

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<https://hdl.handle.net/2066/225439>

Please be advised that this information was generated on 2021-09-22 and may be subject to change.



Enrichment of Rare Variants in Loews–Dietz Syndrome Genes in Spontaneous Coronary Artery Dissection but Not in Severe Fibromuscular Dysplasia

Spontaneous coronary artery dissection (SCAD) is a prime cause of acute myocardial infarction in women < 50 years. Fibromuscular dysplasia (FMD) is present in 17% to 86% of patients with SCAD.¹ In contrast, the prevalence of SCAD in FMD cohorts is <3%.¹ Although the association between these 2 conditions has gained significant interest over the past years, the convergent underlying molecular mechanisms remain elusive.

Familial recurrence studies pointed to a genetic contribution for SCAD and FMD.² In case reports and a small-scale exome sequencing-based cohort study, SCAD has occasionally been linked to *FBN1*, *COL3A1*, and *SMAD3* mutations.² For FMD, a low yield of molecular testing for syndromic thoracic aortic aneurysm and dissection genes has been reported.^{2,3} We aimed to investigate the contribution of rare genetic variants in 25 known thoracic aortic aneurysm and dissection genes to the cause of SCAD and FMD because of the frequent association between the 2 entities. Haloplex-based gene panel sequencing was performed in a large multicenter unrelated patient cohort comprising 179 patients with SCAD±FMD and 102 patients with severe FMD only. The study has full United Kingdom Health Research Authority ethical clearance, and Institutional Review Board approval was obtained from the University of Antwerp and Université Catholique de Louvain. All patients signed informed consent. Variant filtering involved selection of heterozygous nonsynonymous coding or splice site (±2bp and +5bp) variants that are absent in gnomAD v2.1.1, have a minor allele frequency <0.01%, or between 0.01% and 0.1% combined with a CADD score (Combined Annotation Dependent Depletion) >20. After Sanger sequencing validation, selected variants were classified according to the American College of Medical Genetics guidelines. As an independent “control” cohort, gnomAD (genome aggregation database) v2.1.1 (approximately representing the general population) was filtered identically.⁴ Two case–control burden analyses were subsequently performed using Fisher exact (expected values <5) or chi-square statistics (expected values ≥5): SCAD±FMD versus gnomAD and FMD only versus gnomAD. To address the multiple testing burden, the significance of the association tests was evaluated using false discovery rate analysis by means of the *q*-value method. A *q* value <0.05 was considered significant. Segregation analysis was carried out for all filtered variants in the associated genes and (likely) pathogenic variants in the other genes if DNA of relatives was available.

Of the patients with SCAD, 38.5% also showed FMD. Connective tissue disease features (including joint hypermobility or dislocations, thin or smooth or hyperelastic skin, varicose veins, pes planus or talipes, hallux valgus, pectus asymmetry or excavatum/carinatum, inguinal hernia, scoliosis, cutis marmorata, joint pain, easy bruising, striae, atrophic scars, tendon rupture, osteoarthritis) were displayed in 26.3% and extracoronary arterial involvement in 26.3%, and 21.8% had a positive

Aline Verstraeten, PhD

:

Alexandre Persu^{ORCID}, MD, PhD*

David Adlam^{ORCID}, DPhil*

Bart Loews^{ORCID}, MD, PhD*

*Drs Persu, Adlam, and Loews contributed equally.

The full author list is available on page 1023.

Key Words: coronary artery disease ■ fibromuscular dysplasia ■ genetics ■ Loews-Dietz syndrome

© 2020 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

<https://www.ahajournals.org/journal/circ>

Table. Overview of Rare Variants in LDS Genes and (Likely) Pathogenic Variants in Other Thoracic Aortic Aneurysm and Dissection Genes

Gene Variant	MAF gnomAD	ACMG Classification	M/F	CTD	HT	SCAD	FMD	Extracoronary Arterial Involvement	Family History
<i>SMAD2</i> c.619C>G (p.Pro207Ala)	0	VUS (PP2; PM2)	F	N	Y	Cx/RCA
<i>SMAD2</i> c.1082A>C (p.Asn361Thr)	0	LP (PP2-3; PM1-2)	M	Y	Y	LAD	...	Tortuosity carotid/iliac artery	...
<i>SMAD2</i> c.1108C>T (p.Pro370Ser)	0	LP (PP2-3; PM1-2)	F	N	N	RCA	R/CC/other	Arterial dissection	...
<i>SMAD3</i> c.871+1G>A	0	LP (PP3; PM1-2,4)	F	Y	N	LAD	...	Infrarenal aneurysm	Sister: incidentally identified small brain aneurysm (-)
									Brother: splenic aneurysm requiring surgery (+)
									Mother: abdominal aortic rupture (?)
<i>TGFB2</i> c.440C>T (p.Pro147Leu)	4.1E-4	VUS (PM1)	F	N	Y	LAD	R
<i>TGFB2</i> c.440C>T (p.Pro147Leu)	4.1E-4	VUS (PM1)	F	N	N	LAD
<i>TGFB2</i> c.631C>T (p.Arg211Cys)	3.2E-5	VUS (PP3; PM1)	F	N	N	LAD	R/CC	Vertebral artery dissection	...
<i>TGFB2</i> c.740G>T (p.Gly247Val)	0	VUS (PP3; PM1-2)	F	N	N	LAD
<i>TGFB3</i> c.454C>T (p.Arg152Trp)	1.4E-5	VUS (PP3; PM1)	F	Y	N	LAD	R	Common iliac artery aneurysm	...
<i>TGFB3</i> c.463C>T (p.Arg155Trp)	0	VUS (PP3; PM1-2)	F	Y	N	OM2	...	Tortuosity vertebral arteries	...
<i>TGFB3</i> c.813G>C (p.Lys271Asn)	7.4E-5	VUS (PM1)	F	?	Y	Cx	?	...	Brother: thoracic aortic aneurysm (?)
<i>TGFB3</i> c.1202T>C (p.Leu401Pro)	0	LP (PP3,5; PM1-2)	F	N	N	...	NA	...	Father: abdominal and thoracic aortic aneurysm (+)
<i>TGFB1</i> c.739G>A (p.Glu247Lys)	0	VUS (PP3; PM1-2)	M	N	N	LAD
<i>TGFB1</i> c.1499G>C (p.Gly500Ala)	4.0E-6	VUS (-)	F	N	Y	LAD	R/CC	Arterial dissection	...
<i>TGFB2</i> c.1082A>G (p.Tyr361Cys)	0	VUS (PP3; PM1-2)	F	N	Y	NA	...	CC aneurysm and arterial dissection	...
<i>TGFB2</i> c.1718C>T (p.Ser573Leu)	1.6E-5	VUS (PP3)	F	N	N	RDP	R
<i>TGFB2</i> c.1396+5G>T	0	LP (PP3; PM2,4,6)	F	Y	N	Cx	(de novo)
<i>LOX</i> c.893T>G (p.Met298Arg)	0	P (PP3; PM1-2; PS1,3)	F	Y	Y	Cx	R	...	Mother: brain aneurysm (?)
<i>FLNA</i> c.3806G>A (p.Gly1269Asp)	0	LP (PP2-3; PM2,4)	F	N	Y	LAD	...	Mild aortic dilation	Mother: thoracic aortic aneurysm and rupture (?)
									Daughter: BAV with mild ascending aortic aneurysm (?)
<i>COL3A1</i> c.737delG (p.Gly246Aspfs*17)	0	P (PP3; PM2; PVS1)	F	N	?	...	R	Arterial aneurysm	...
<i>COL3A1</i> c.2177G>T (p.Gly726Val)	0	LP (PP2-3; PM1-2,5)	F	N	Y	LAD/Cx

Extracoronary arterial involvement includes tortuosity, aneurysm, or dissection of noncoronary arteries. Family history is deemed positive on documentation of at least 1 first- or second-degree relative with SCAD, FMD, or arterial aneurysm/dissection. ? indicates unknown variant status; (-), variant is absent; (+), variant is present; ACMG, American College of Medical Genetics; BAV, bicuspid aortic valve; CC, cervico-cephalic; CTD, connective tissue disease findings; Cx, circumflex coronary artery; F, female; FMD, fibromuscular dysplasia; gnomAD, genome aggregation database; HT, hypertension; LAD, left anterior descending coronary artery; LDS, Loey's-Dietz syndrome; LP, likely pathogenic; M, male; MAF, minor allele frequency; N, no; NA, yes, but the location is unknown; OM2, obtuse marginal 2; P, pathogenic; R, renal; RCA, right coronary artery; RDP, right descending posterior coronary artery; SCAD, spontaneous coronary artery dissection; TAAD, thoracic aortic aneurysm and dissection; VUS, variant of uncertain significance; and Y, yes.

family history. In the FMD-only cohort, these frequencies were 0%, 84.3%, and 2.9%, respectively. Multifocal FMD was observed in 84.3% of cases, and in 46.1% of patients, FMD was observed in multiple vascular beds.

In the single-gene burden analyses, only *SMAD2* reached significant enrichment for rare variants in patients with SCAD±FMD compared with the general population after false discovery rate correction (3/358 [0.8%] versus 172/241 932 [0.1%], $P=1E-3$, $q=1.7E-2$). However, we did observe a higher frequency of variants in all 6 Loews–Dietz syndrome (LDS) genes (ie, *TGFBR1/2*, *SMAD2/3*, *TGFB2/3*; Table). A combined LDS gene burden analysis confirmed a highly significant P value surviving false discovery rate correction (16/358 [4.5%] versus 3485/235 972 [1.5%]; $P=3E-6$, $q=1E-4$). The patient cohort with variants in the LDS genes was not statistically significantly different from the whole SCAD±FMD cohort with respect to sex, age at SCAD event, family history, SCAD location, FMD co-occurrence, connective tissue disease findings, history of hypertension, and concurrence with extracoronary tortuosity or aneurysm/dissection. None of the variant carriers was clinically diagnosed with LDS or presented with the typical LDS triad, suggesting that these variants can cause a milder phenotype. Segregation analysis in the limited number of relatives from which DNA was available hints to variable expressivity (Table). Although no significance was reached for the other analyzed thoracic aortic aneurysm and dissection genes, we also identified likely pathogenic variants in *COL3A1*, *FLNA*, and *LOX* in patients with SCAD±FMD with a positive family history of arteriopathy (Table). Whereas pathogenic *COL3A1* variants were described in patients with SCAD previously,² *FLNA* and *LOX* variants have not. Altogether, thoracic aortic aneurysm and dissection panel analysis of the SCAD±FMD cohort reached a rare variant uptake of 10.6%.

Despite previous identification of elevated TGFB1 and TGFB2 plasma levels in patients with mostly severe FMD,² neither the single-gene analyses nor combined LDS gene analysis (1/204 [0.5%] versus 3485/235 972 [1.5%]; $P=3.8E-1$) yielded significant P values in our FMD-only series. However, we did identify 1 multifocal FMD patient with a *TGFB3* variant (p.Leu401Pro) that was previously reported in LDS,⁵ and for the first time identified a patient with FMD (multifocal) with a pathogenic *COL3A1* variant (p.Gly246Aspfs*17).

In conclusion, we demonstrated that rare variants in the known LDS genes impinge on SCAD risk, implying a pathophysiological role for dysregulated transforming growth factor β signaling and, hence, opening new avenues for SCAD research and future prevention and therapy. Although validation in other SCAD cohorts is warranted, our results advocate for routine molecular diagnostic screening of LDS genes in patients with SCAD, even in those without

connective tissue disease manifestations. We showed that pathogenic *FLNA* and *LOX* variants are occasionally found in SCAD±FMD cases and revealed the presence of pathogenic *COL3A1* variants in both patients with SCAD±FMD and patients with FMD only.

Gene panel sequencing was done for *ACTA2*, *BGN*, *COL3A1*, *ELN*, *EMILIN1*, *FBN1/2*, *FLNA*, *FOXE3*, *LOX*, *MAT2A*, *MFAP5*, *MYH11*, *MYLK*, *NOTCH1*, *PRKG1*, *SKI*, *SMAD2/3/4/6*, *TGFB2/3*, and *TGFBR1/2*. For all samples, at least 99% of the target region was covered at $\geq 30\times$. The following transcripts were used to annotate all variants in the associated genes or (likely) pathogenic variants in any of the other genes: ENST00000402690, ENST00000327367, ENST00000366929, ENST00000238682, ENST00000374994, ENST00000359013, ENST00000304636, ENST00000369850, and ENST00000231004.

ARTICLE INFORMATION

Data sharing: The data that support the findings of this study are available from the corresponding author upon reasonable request.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.120.045946>.

Authors

Aline Verstraeten, PhD; Melanie H.A.M. Perik, MSc; Anna A. Baranowska¹, MSc; Josephina A.N. Meester, PhD; Lotte Van Den Heuvel, MSc; Jarl Bastianen, MSc; Marlies Kempers, MD, PhD; Ingrid P.C. Krapels, MD, PhD; Angela Maas, MD, PhD; Andrea Rideout, MSc; Anthony Vandersteen, MD, PhD; Glenda Sobey, MD; Diana Johnson, MSc; Erik Fransen, PhD; Neeti Ghali², MD; Tom Webb³, PhD; Abtehale Al-Hussaini, MBBS; Peter de Leeuw⁴, MD, PhD; Philippe Delmotte, MD; Marelucy Lopez-Sublet, MD; Marco Pappaccogli⁵, MD; Muriel Sprynger⁶, MD; Laurent Toubiana, PhD; European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI); Lut Van Laer, PhD; Fleur S. Van Dijk, MD, PhD; Miikka Vikkula⁷, MD, PhD; Nilesh J. Samani, MD; Alexandre Persu⁸, MD, PhD; David Adlam⁹, DPhil; Bart Loews¹⁰, MD, PhD

Correspondence

Correspondence to Bart Loews, MD, PhD, Center of Medical Genetics, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital Prins Boudewijnlaan 43, 2650 Antwerp, Belgium; or David Adlam, MD, PhD, Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, United Kingdom. Email bart.loews@uantwerpen.be or da134@le.ac.uk

Affiliations

Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Belgium (A. Verstraeten, M.H.A.M.P., J.A.N.M., L.V.D.H., J.B., E.F., L.V.L., B.L.). Department of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (A.A.B., T.W., A.A.-H., N.J.S., D.A.). Department of Human Genetics (M.K., B.L.), Department of Cardiology (A.M.), Radboud University Nijmegen Medical Center, The Netherlands. Department of Clinical Genetics (I.P.C.K.), Department of Medicine (P.D.L.), Maastricht University Medical Centre, The Netherlands. Maritime Medical Genetics Service, Izaak Walton Killam Health Centre, Halifax, Canada (A.R., A. Vandersteen). Division of Medical Genetics, Department of Pediatrics, Dalhousie University, Halifax, Canada (A. Vandersteen). Ehlers Danlos Syndrome National Diagnostic Service, Sheffield Clinical Genetics Department, Northern General Hospital, United Kingdom (G.S., D.J.). StatUa Center for Statistics, University of Antwerp, Belgium (E.F.). Ehlers-Danlos Syndrome, National Diagnostic Service, Northwick Park and St. Mark's Hospitals, Harrow, United Kingdom (N.G., F.S.V.D.). Division of Cardiology, Centre Hospitalier Universitaire Ambroise

Paré, Mons, Belgium (P.D.). Department of Internal Medicine, European Society of Hypertension Excellence Centre, Centre Hospitalier Universitaire (CHU) Avicenne, assistance publique hôpitaux de paris (AP-HP), Bobigny, France (M.L.-S.). Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Division of Cardiology, Cliniques Universitaires Saint-Luc (M.P., A.P.), Human Molecular Genetics, de Duve Institute (M.V.), Université Catholique de Louvain, Brussels, Belgium. Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Turin, Italy (M.P.). Cardiology Department, University of Liège Hospital, Belgium (M.S.). Sorbonne Université, Université Paris 13, Sorbonne Paris Cité, Institut national de la santé et de la recherche médicale (INSERM), UMR_S 1142, Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé (LIMICS), Institut de recherche pour la valorisation des données de santé (IRSAN), France (L.T.).

Acknowledgments

We are grateful for the support of SCAD and FMD survivors. We thank our clinical colleagues who have referred SCAD and FMD cases to our research study. In the United Kingdom we specifically acknowledge the support of Alice Wood, Ellie Clarke, Jenny Middleton, Jane Plume, and Donna Alexander for all their support in the SCAD research. We acknowledge the leadership of the European Society of Cardiology - Acute Cardiovascular Care Association (ESC-ACCA) SCAD Study Group. In addition, we thank Ulrike Schwarze for her contribution to the molecular part of this study. We acknowledge the VASCERN (European Reference Network on Rare Vascular Disorders). Drs Loeys and Verstraeten are members of the VASCERN Heritable Thoracic Aortic Diseases (HTAD) and Medium Sized Arteries (MSA) working groups. Dr Vikkula is a member of the Vascular Anomalies (VASCA) working group.

Sources of Funding

This research was supported by funding from the University of Antwerp (GOA, Methusalem-OEC grant "Genomed" FFB190208), the Research Foundation - Flanders (G.0356.17), the Dutch Heart Foundation (2013T093), the Marfan Foundation, the Fonds de la Recherche Scientifique (T.0026.14), BeatSCAD, the British Heart Foundation (PG/13/96/30608), the National Institute of Health Research Rare Disease Translational Collaboration, and the Leicester National Institute of Health Research Biomedical Research Center. Dr Loeys is a senior clinical investigator of the Research Foundation - Flanders and holds a consolidator grant from the European Research Council (Genomia - ERC-COG-2017-771945). Drs Verstraeten and Meester hold postdoctoral fellowships of the Research Foundation - Flanders, and Ms Van Den Heuvel is supported by a Research Foundation - Flanders PhD scholarship.

Disclosures

Dr Adlam has received research funding from Abbott Vascular Inc to support a clinical research fellow. He has also received funding and support from Astra

Zeneca Inc for genetics research into SCAD. He has undertaken unrelated consultancy for GE Inc. The other authors report no conflicts.

APPENDIX

Collaborators of the European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)

Alexandre Persu¹, Marco Pappaccogli², Christophe Beauloye, Patrick Chen, Frank Hammer, Pierre Goffette, Parla Astarci, André Peeters, Robert Verhelst, Miikka Vikkula³, Patricia Van der Niepen, Frank Van Tussenbroek, Tine De Backer, Sofie Gevaert, Dimitri Hemelsoet, Luc Defreyne, Hilde Heuten, Laetitia Yperzeele, Thijs Van der Zijden, Jean-Philippe Lengelé, Jean-Marie Krzesinski, Muriel Sprynger⁴, Philippe Delmotte, Peter Verhamme, Thomas Vanassche, Pasquale Scoppettuolo, Jean-Claude Wautrecht, Bojan Jelaković, Zivka Dika, Rosa Maria Bruno, Stefano Taddei, Caterina Romanini, Ilaria Petrucci, Franco Rabbia, Marco Pappaccogli⁵, Silvia Di Monaco, Gian Paolo Rossi, Silvia Lerco, Pietro Minuz, Giancarlo Mansueto, Sergio De Marchi, Denise Marcon, Bram Kroon, Peter de Leeuw⁶, Wilko Spiering, Bert-Jan van den Born, Esteban Poch, Enrique Montagud-Marrahi, Alicia Molina, Elena Guillen, Marta Burrell, Gregor Wuerzner, Lucia Mazzolai, Giacomo Buso

REFERENCES

- Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, Ganesh SK, Gulati R, Lindsay ME, Mieres JH, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation*. 2018; 137:e523–e557. doi: 10.1161/CIR.0000000000000564
- Maas AHEM, Bouatia-Naji N, Persu A, Adlam D. Spontaneous coronary artery dissections and fibromuscular dysplasia: current insights on pathophysiology, sex and gender. *Int J Cardiol*. 2019;286:220–225. doi: 10.1016/j.ijcard.2018.11.023
- Poloskey SL, Kim ESH, Sanghani R, Al-Quthami AH, Arscott P, Moran R, Rigelsky CM, Gornik HL. Low yield of genetic testing for known vascular connective tissue disorders in patients with fibromuscular dysplasia. *Vasc Med*. 2012;17:371–378. doi: 10.1177/1358863X12459650
- Gillis E, Kumar AA, Luyckx I, Preuss C, Cannaeerts E, van de Beek G, Wieschendorf B, Alaerts M, Bolar N, Vandeweyer G, et al. Candidate gene resequencing in a large bicuspid aortic valve-associated thoracic aortic aneurysm cohort: SMAD6 as an important contributor. *Front Physiol*. 2017;8:400. doi: 10.3389/fphys.2017.00400
- Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JMA, de Graaf BM, van de Beek G, Gallo E, Kruithof BPT, Venselaar H, Myers LA, et al. Mutations in a TGF- β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. *J Am Coll Cardiol*. 2015;65:1324–1336. doi: 10.1016/j.jacc.2015.01.040